Therapeutics News and Research

RSS

Halozyme Therapeutics offers to sell 8.3 million shares of common stock

Halozyme Therapeutics, Inc. today announced that it is offering to sell 8.3 million shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering

9 Sep 2010

Zyngenia completes $15M Series A financing extension from NEA

Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.

8 Sep 2010

BioMed Realty Trust expands San Diego property portfolio to 1.8M rentable square feet

BioMed Realty Trust, Inc. today announced that it has entered into definitive agreements to acquire five properties, comprised of 14 life science buildings with approximately 405,000 square feet of laboratory and office space, in San Diego's primary life science submarkets of University Towne Centre, Torrey Pines and Sorrento Valley.

8 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

PPTA supports CMS' proposal for hospital outpatient reimbursement for plasma protein therapies

The Plasma Protein Therapeutics Association (PPTA) recommends that the Centers for Medicare and Medicaid Services (CMS) finalize its Proposed Rule regarding reimbursement to better ensure patient access to vital medicines in the hospital outpatient setting.

8 Sep 2010

Silence Therapeutics receives two patents for RNA interference therapeutics

Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).

8 Sep 2010

NGP 555 compound effective in preventing amyloid pathology of Alzheimer's disease

In the Sept. 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer's disease (AD) in a transgenic mouse model.

8 Sep 2010

Researchers discover tolerance mechanism in chronic morphine treatment

Researchers from Mount Sinai School of Medicine have discovered a major mechanism underlying the development of tolerance to chronic morphine treatment. The discovery may help researchers find new therapies to treat chronic pain, and reduce tolerance and side effects associated with morphine use. The findings are published in the July 20th issue of Science Signaling.

8 Sep 2010

Quick increase of calcium concentration in cells rapidly trigger Aurora-A kinase enzyme activity

Aurora-A kinase (AurA) is an enzyme that is hyperactive in many cancers and drives tumor cell proliferation. Several AurA inhibitors are currently being tested in clinical trials to see if they slow tumor growth. Now, researchers in the Developmental Therapeutics Program at Fox Chase Cancer Center have identified an activation signal for AurA. They report in the September 7 issue of Nature Communications that a quick increase in the calcium concentration in a cell rapidly triggers AurA kinase activity.

8 Sep 2010

Tikcro reports $3.2 million net loss for second-quarter 2010

Tikcro Technologies Ltd. today reported results for the second quarter and six months ended June 30, 2010.

7 Sep 2010

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

7 Sep 2010

Researchers develop new animal model for studying hemophilia A

Researchers at Yale School of Medicine have developed a new animal model for studying hemophilia A, with the goal of eventually treating people with the disorder.

3 Sep 2010

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.

3 Sep 2010

Emerald BioStructures, SomaLogic announce strategic collaboration for SOMAmers

Emerald BioStructures, a leading provider of integrated structural biology services, and SomaLogic, Inc., a diagnostics and biomarker discovery company, today announced that they have entered into a strategic collaboration for the structure-based design of chemically modified DNA aptamers and small molecule therapeutics, based on crystal structures of important protein targets bound to high affinity SOMAmers.

3 Sep 2010

International study to improve treatments for Duchenne muscular dystrophy

A large international study aimed at improving the care of muscular dystrophy patients worldwide is being launched by physicians, physical therapists, and researchers at the University of Rochester Medical Center.

3 Sep 2010

Celldex Therapeutics regains worldwide rights to commercialize rindopepimut therapeutic cancer vaccine

Celldex Therapeutics, Inc. announced today it will regain full worldwide rights to develop and commercialize rindopepimut (CDX-110), effective November 1, 2010.

3 Sep 2010

First direct evidence that X-linked TLR7 gene promotes lupus in humans

Lupus Research Institute-funded researcher Betty Tsao, PhD, at the University of California Los Angeles has discovered that humans-males in particular-with a variant form of the immune receptor gene "Toll Like Receptor 7 (TLR7)" are at increased risk of developing the autoimmune disease systemic lupus erythematosus (lupus). This breakthrough finding offers renewed hope for developing more targeted treatments.

3 Sep 2010

BARDA awards contract to develop treatment for ionizing radiation exposure

The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) today awarded a $153 million contract to Cellerant Therapeutics, Inc. of San Carlos, Calif., to continue developing a new way to treat an illness caused by exposure to high levels of ionizing radiation which can damage the body's cells - the type of radiation that would come from a nuclear blast.

3 Sep 2010

Californians recognized for contributing to plasma protein lifesaving therapies

This month, Californians are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that makes the creation of these unique therapies possible.

3 Sep 2010

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues.

3 Sep 2010

Therapeutics News and Research

Halozyme Therapeutics offers to sell 8.3 million shares of common stock

Zyngenia completes $15M Series A financing extension from NEA

BioMed Realty Trust expands San Diego property portfolio to 1.8M rentable square feet

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

PPTA supports CMS' proposal for hospital outpatient reimbursement for plasma protein therapies

Silence Therapeutics receives two patents for RNA interference therapeutics

NGP 555 compound effective in preventing amyloid pathology of Alzheimer's disease

Researchers discover tolerance mechanism in chronic morphine treatment

Quick increase of calcium concentration in cells rapidly trigger Aurora-A kinase enzyme activity

Tikcro reports $3.2 million net loss for second-quarter 2010

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Researchers develop new animal model for studying hemophilia A

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

Emerald BioStructures, SomaLogic announce strategic collaboration for SOMAmers

International study to improve treatments for Duchenne muscular dystrophy

Celldex Therapeutics regains worldwide rights to commercialize rindopepimut therapeutic cancer vaccine

First direct evidence that X-linked TLR7 gene promotes lupus in humans

BARDA awards contract to develop treatment for ionizing radiation exposure

Californians recognized for contributing to plasma protein lifesaving therapies

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News